glatiramer acetate / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
COMBAT-MS, NCT03193866 / 2016-003587-39: COMparison Between All immunoTherapies for Multiple Sclerosis.

Active, not recruiting
N/A
3526
Europe
Rituximab, Natalizumab, Fingolimod, Alemtuzumab, Interferon-beta, Glatiramer acetate, Dimethyl Fumarate
Karolinska Institutet, Patient-Centered Outcomes Research Institute, Kaiser Foundation Research Institute
Relapsing-remitting Multiple Sclerosis
12/22
12/22
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis ().

Recruiting
N/A
130
Europe
DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide
VU University Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
08/23
01/24
NCT03209479: Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Completed
N/A
1332
Japan
Glatiramer acetate, Copaxone subcutaneous injection syringe
Teva Takeda Pharma Ltd.
Multiple Sclerosis
03/24
03/24
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
AIOLOS, NCT05344469: A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis

Recruiting
N/A
800
Europe
ofatumumab, glatiramer acetate, interferon β1
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/26
12/26
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31

Download Options